Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir

Saved in:

Bibliographic Details
Main Authors:	Ana Pelufo-Pellicer, MªÁngeles López-Montenegro Soria
Format:	Article
Language:	English
Published:	Elsevier 2017-03-01
Series:	Farmacia Hospitalaria
Online Access:	http://www.aulamedica.es/fh/pdf/10685.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form
by: A. V. Sulebhavikar, et al.
Published: (2008-01-01)

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
by: Dóra Paróczai, et al.
Published: (2025-01-01)

The Palatability of Lopinavir and Ritonavir Delivered by an Innovative Freeze-Dried Fast-Dissolving Tablet Formulation
by: David W. Pittman, et al.
Published: (2018-01-01)

Persistent hepatocyte secretory failure in lopinavir/ritonavir related to drug-induced liver injury: a case report
by: Yue Sun, et al.
Published: (2025-02-01)

Lopinavir and Ritonavir have High Affinity Toward the SARS-CoV-2 S-protein Receptor-binding Domain Sequenced in Brazil
by: Aline Diogo Marinho, et al.
Published: (2025-01-01)

Functional Role of P-Glycoprotein and Binding Protein Effect on the Placental Transfer of Lopinavir/Ritonavir in the Ex Vivo Human Perfusion Model
by: Pierre-Francois Ceccaldi, et al.
Published: (2009-01-01)

International Normalized Ratio (INR) Increases amongst Two Patients Living with HIV on Warfarin after Being Switched from a Nevirapine to a Dolutegravir-Based Antiretroviral Regimen
by: Natalie Sang, et al.
Published: (2021-01-01)

Acute Warfarin Toxicity as Initial Manifestation of Metastatic Liver Disease
by: Varalaxmi Bhavani Nannaka, et al.
Published: (2016-01-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01)

Determining the effect of drug "Warfarin sodium" on toxicity indicators in an acute experiment
by: D.O. Hlavachek, et al.
Published: (2023-09-01)

Impact of switching to a dolutegravir‐based regimen on body weight changes: insights from West African adult HIV cohorts
by: Thierry Tiendrebeogo, et al.
Published: (2024-12-01)

Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy
by: Defa Huang, et al.
Published: (2024-12-01)

Acute kidney injury and tacrolimus toxicity in a kidney transplant recipient treated with nirmaltrevir/ritonavir: a case report
by: Jack Rycen, et al.
Published: (2024-12-01)

Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species.
by: Nicolas Burns, et al.
Published: (2024-01-01)

Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species
by: Nicolas Burns, et al.
Published: (2024-01-01)

Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir/Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial
by: Barbara Rossetti, et al.
Published: (2024-11-01)

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
by: Jan Gerstoft, et al.
Published: (2023-08-01)

Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01)

Effect of quercetin on the transport of ritonavir to the central nervous system in vitro and in vivo
by: Liang Gongwen, et al.
Published: (2016-03-01)

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
by: Ping Xu, et al.
Published: (2024-12-01)

Diffuse Alveolar Hemorrhage Associated with Warfarin Therapy
by: Bülent Kaya, et al.
Published: (2015-01-01)

Warfarin-Associated Diaphragmatic Hernia: An Unusual Diagnosis
by: Cristina Vilhena, et al.
Published: (2015-01-01)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
by: Douglas Ward, et al.
Published: (2020-01-01)

Impaired creatinine-based estimated glomerular filtration rate in Thai individuals switching to dolutegravir: illustrating the role of cystatin C testing to aid clinical decision making
by: Carlo Sacdalan, et al.
Published: (2025-02-01)

New warfarin anticoagulation management model after heart valve surgery: rationale and design of a prospective, multicentre, randomised trial to compare an internet-based warfarin anticoagulation management model with the traditional warfarin management model
by: Yan Li, et al.
Published: (2019-12-01)

Screening of Polymers for Oral Ritonavir Amorphous Solid Dispersions by Film Casting
by: Ayse Nur Oktay, et al.
Published: (2024-10-01)

Presumptive Haematomyelia Secondary to Warfarin Toxicosis in a Dog
by: Carlos Blanco, et al.
Published: (2022-01-01)

Determining Risk Factors of Bleeding in Patients on Warfarin Treatment
by: Evren Uygungül, et al.
Published: (2014-01-01)

ADVANTAGES AND DISADVANTAGES OF WARFARIN AND PRADAXA THERAPY FOR VENOUS THROMBOEMBOLISM
by: B. S. Sukovatykh, et al.
Published: (2018-01-01)

Risk of development of hemorrhagic complications due to warfarin therapy
by: O. I. Filippova, et al.
Published: (2017-12-01)

Ritonavir loaded solid lipid nanoparticles for oral drug delivery and bioavailability enhancement
by: Ananda Kumar Chettupalli, et al.
Published: (2025-01-01)

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
by: Andrea Di Lenarda, et al.
Published: (2024-08-01)

Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review
by: William R. Short, et al.
Published: (2024-12-01)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
by: Alessandra Latini, et al.
Published: (2019-12-01)

Naoxintong Is Involved in the Coagulation Regulation of Warfarin Through the MAPK Pathway
by: Luo X, et al.
Published: (2025-01-01)

Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
by: Muhammed Sherid, et al.
Published: (2016-01-01)

Intestinal Tuberculosis Presenting with Gastrointestinal Bleeding in Patient on Warfarin Therapy
by: Werimo Pascal Kuka, et al.
Published: (2022-01-01)

Diffuse Alveolar Hemorrhage Caused by Warfarin after Rifampicin Discontinuation
by: Takashige Kiyota, et al.
Published: (2019-01-01)

Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV.
by: Shu-Yuan Lee, et al.
Published: (2024-01-01)